Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ETNBNYSE:OGNNASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$71.68+0.1%$66.93$47.88▼$107.37$3.94B0.32517,617 shs395,034 shsETNB89bio$8.47+3.5%$8.80$5.99▼$13.71$1.24B1.172.43 million shs959,639 shsOGNOrganon & Co.$15.34+2.5%$15.46$13.87▼$23.10$3.96B0.762.35 million shs3.03 million shsPTCTPTC Therapeutics$54.50+3.3%$48.60$24.00▼$57.04$4.30B0.66740,652 shs861,892 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-1.57%+4.34%+13.33%-14.58%+1.46%ETNB89bio-2.04%-1.56%-26.83%+6.37%-38.54%OGNOrganon & Co.-0.39%+0.75%+0.04%-2.12%-19.32%PTCTPTC Therapeutics-1.59%-0.08%+8.49%+13.78%+71.35%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.3411 of 5 stars3.61.00.00.03.72.50.0ETNB89bio2.8825 of 5 stars4.51.00.00.02.51.70.6OGNOrganon & Co.4.873 of 5 stars3.22.03.33.73.41.73.1PTCTPTC Therapeutics3.2435 of 5 stars3.31.00.04.42.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$108.4651.31% UpsideETNB89bio 2.90Moderate Buy$27.56225.33% UpsideOGNOrganon & Co. 2.43Hold$20.8035.63% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$64.0017.43% UpsideCurrent Analyst Ratings BreakdownLatest ETNB, PTCT, OGN, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/14/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$72.00 ➝ $78.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/7/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.002/28/2025ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $21.002/28/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $72.002/19/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)2/18/2025PTCTPTC TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $63.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M36.49N/AN/A$9.97 per share7.19ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AOGNOrganon & Co.$6.40B0.62$4.92 per share3.12($0.27) per share-56.80PTCTPTC Therapeutics$806.78M5.33$2.62 per share20.80($10.85) per share-5.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)ETNB89bio-$142.19M-$3.43N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)OGNOrganon & Co.$864M$3.334.614.100.9013.49%431.62%8.03%5/1/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)Latest ETNB, PTCT, OGN, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AOGNOrganon & Co.$1.127.30%+25.99%33.63%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ALatest ETNB, PTCT, OGN, and ACLX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29ETNB89bio0.0911.6611.66OGNOrganon & Co.17.731.701.21PTCTPTC TherapeuticsN/A2.102.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ETNB89bioN/AOGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%ETNB89bio2.80%OGNOrganon & Co.1.40%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8054.94 million50.70 millionOptionableETNB89bio40145.98 million103.15 millionOptionableOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableETNB, PTCT, OGN, and ACLX HeadlinesRecent News About These CompaniesJPMorgan ups PTC Therapeutics target, adds to Focus ListMarch 14 at 10:13 PM | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 14 at 2:41 AM | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by BrokeragesMarch 14 at 2:39 AM | marketbeat.comBank of America Upgrades PTC Therapeutics (NASDAQ:PTCT) to NeutralMarch 13 at 1:45 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Upgraded by Bank of America to "Neutral" RatingMarch 12 at 8:12 AM | marketbeat.comGC Wealth Management RIA LLC Purchases Shares of 8,032 PTC Therapeutics, Inc. (NASDAQ:PTCT)March 12 at 5:34 AM | marketbeat.comB of A Securities Upgrades PTC Therapeutics (PTCT)March 11 at 9:40 PM | msn.comSPX Gestao de Recursos Ltda Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)March 11 at 6:13 AM | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated by Analysts at ScotiabankMarch 10, 2025 | americanbankingnews.comProficio Capital Partners LLC Acquires Shares of 16,792 PTC Therapeutics, Inc. (NASDAQ:PTCT)March 9, 2025 | marketbeat.comMorgan Stanley Reaffirms Overweight Rating for PTC Therapeutics (NASDAQ:PTCT)March 9, 2025 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Receives Overweight Rating from Morgan StanleyMarch 8, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at ScotiabankMarch 8, 2025 | marketbeat.comCandriam S.C.A. Decreases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)March 8, 2025 | marketbeat.comAigen Investment Management LP Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)March 8, 2025 | marketbeat.comCantor Fitzgerald Analysts Raise Earnings Estimates for PTCTMarch 8, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $63,369.60 in StockMarch 7, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 1,230 SharesMarch 7, 2025 | insidertrades.comCantor Fitzgerald Analysts Boost Earnings Estimates for PTCTMarch 7, 2025 | marketbeat.comQ1 Earnings Estimate for PTCT Issued By William BlairMarch 3, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Annual Earnings And Analysts Are Lifting Their EstimatesMarch 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentBy Gabriel Osorio-Mazilli | February 14, 2025View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide InvestmentArcher Aviation Stock Skids: Mistaking Progress for Bad News?By Chris Markoch | February 24, 2025View Archer Aviation Stock Skids: Mistaking Progress for Bad News?Hims & Hers: From Viral Ad to Volatile StockBy Jeffrey Neal Johnson | February 18, 2025View Hims & Hers: From Viral Ad to Volatile StockETNB, PTCT, OGN, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$71.68 +0.10 (+0.14%) Closing price 04:00 PM EasternExtended Trading$71.62 -0.06 (-0.08%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.89bio NASDAQ:ETNB$8.47 +0.29 (+3.55%) Closing price 04:00 PM EasternExtended Trading$8.48 +0.00 (+0.06%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Organon & Co. NYSE:OGN$15.34 +0.38 (+2.51%) Closing price 03:58 PM EasternExtended Trading$15.28 -0.06 (-0.40%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$54.50 +1.74 (+3.30%) Closing price 04:00 PM EasternExtended Trading$54.49 -0.01 (-0.02%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead How Super Micro Computer Stock Is Defying the Market Sell-Off Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus D-Wave Quantum Stock Jumps on "Quantum Supremacy" News Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
